EGFR and lung cancer: Erlotinib is an EGFR-specific TKI that has been approved by the Food and Drug Administration to be used as a molecularly targeted drug for lung cancer patients (Sierra et al., 2010; Diep et al., 2011; Kosaka et al., 2011).